Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/25/2008US20080234314 2-(6-bromobenzo[d][1,3]dioxol-5-ylthio)-1-(pent-4-ynyl)-1H-imidazo [4,5-c]pyridin-4-amine; cancer, an autoimmune disease, or a neurodegenerative disease; ubiquitous chaperone protein inhibitors
09/25/2008US20080234313 Novel inhibitors
09/25/2008US20080234312 Feed or Feed Additive Containing an Alkaloid
09/25/2008US20080234311 IMMUNOASSAY FOR DETECTION AND QUANTIFICATION OF AMYLOID-beta PEPTIDES
09/25/2008US20080234310 Administering cis(+-) 2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole; prolonging lifespan, improving quality of life
09/25/2008US20080234309 Macrocyclic lactone compounds and methods for their use
09/25/2008US20080234308 Amino-Aza-Adamantane Derivatives and Methods of Use
09/25/2008US20080234307 Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics
09/25/2008US20080234306 (S)-17-Cyclopropylmethyl-4,5 alpha -epoxy-3,14-dihydroxymorphinan N-oxide and an opioid agonist; significant mu-opioid receptor antagonistic activity; reducing opioid side-effects, dysphoria, pruritis, urinary retention, nausea, emesis
09/25/2008US20080234305 Novel Tetrahydropyridine Derivatives
09/25/2008US20080234304 N3-Pyridyl-Thiamine And Its Use In Cancer Treatments
09/25/2008US20080234303 Inhibitors of the FAK (focal adhesion kinase) protein tyrosine kinases, antiproliferative, antitumor; for example 5-{4-[(1-Hydroxy-cyclopentylmethyl)-amino]-5-trifluoromethyl-pyrimidin-2-ylamino}-1,3-dihydro-indol-2-one
09/25/2008US20080234302 Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
09/25/2008US20080234301 Alpha-4 Integrin Mediated Cell Adhesion Inhibitors for the Treatment or Prevention of Inflammatory Diseases
09/25/2008US20080234300 Pyrimido[5,4-c] Quinoline-2, 4-Diamine Derivatives and Methods of Use Thereof
09/25/2008US20080234299 Quinazolinones
09/25/2008US20080234298 Administering antifolate anticancer agent and methoxyamine to enhance or increase the effect of the antifolate anticancer agent
09/25/2008US20080234297 HSP90 Inhibitors Containing a Zinc Binding Moiety
09/25/2008US20080234296 Triazolo[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists
09/25/2008US20080234294 Administering compounds such as 1,3-Dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea for therapy of Warts Hypogammaglobulinemia Immunideficiency Myelokathexis; neutropenia, hypogammaglobulinemia or HPV infection
09/25/2008US20080234293 Tri-aryl/heteroaromatic cannabinoids and use thereof
09/25/2008US20080234292 Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents
09/25/2008US20080234291 Apolipo-protein B (apoB) secretion and microsomal triglyceride transfer protein (MTP) inhibiting properties; hyperlipidemia, obesity, or type II diabetes; solubility, taste modifying agent and an antioxidant
09/25/2008US20080234290 New indole or benzimidazole derivatives as cb1 inverse agonists
09/25/2008US20080234289 Melanocortin Receptor-Specific Compounds
09/25/2008US20080234288 Using compounds such as {3-[(2-Acetylamino-benzooxazole-6-sulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid thiazol-5-ylmethyl ester; HCV infections
09/25/2008US20080234287 Lung cancer, gastric cancer, liver cancer, leucocythemia, endometrioma, oophoroma, mammary cancer, colon cancer, prostatic cancer, or pituitary gland cancer; N (N',N'-dimethylaminoethyl)benzo[b]thieno[2,1-c]naphthalimide
09/25/2008US20080234286 Spray dried, stable, free-flowing solid; purity; inhibitor of tyrosine kinases and is indicated for the treatment of chronic myeloid leukemia
09/25/2008US20080234285 Renin inhibitor such as (S),4(S),5(S),7(S) N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide and PDGF receptor tyrosine kinase inhibitor such as Imatinib, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis
09/25/2008US20080234284 Pyrazolo[1,5-a]Pyrimidin-7-Yl Amine Derivatives as Protein Kinase Inhibitors
09/25/2008US20080234283 Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
09/25/2008US20080234282 Especially 1-(2-(naphthylmethoxy)-1-phenylethyl)piperazine derivatives: 4-{[2-(3,chloro-4-fluorophenyl)-2-piperazin-1-ylethoxy]methyl}-3-methoxy-2-naphthonitrile; neurokinin 1 antagonists; antidepressants
09/25/2008US20080234281 2,3-Dihydrooxadiazoles such as 3-acetyl-5-(2,5-difluorophenyl)-2-phenyl-2,3-dihydro-1,3,4-oxadiazole and 3-[3-acetyl-5-(2,5-difluorophenyl)-2-phenyl-2,3-dihydro-1,3,4-oxadiazol-2-yl]-N,N-dimethylpropan-1-amine that are useful for treating cancer
09/25/2008US20080234280 Use of Mc4 Receptor Agonist Compounds
09/25/2008US20080234279 Ecteinascidins
09/25/2008US20080234278 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
09/25/2008US20080234277 Novel aza-pyridopyrimidinone derivatives
09/25/2008US20080234276 Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors
09/25/2008US20080234275 Administering 1-(4-thio-beta-D-arabinofuranosyl)cytosine; rheumatoid arthritis
09/25/2008US20080234274 Novel Compounds
09/25/2008US20080234273 Such as 3-{[4-(azetidin-1-ylcarbonyl)-2-chlorophenyl]oxy}-5-({(1S)-2-[(difluoromethyl)oxy]-1-methylethyl}oxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide; glucokinases (Glk)
09/25/2008US20080234272 Novel Piperazines as Antimalarial Agents
09/25/2008US20080234271 Arylphenylamino- and Arylphenylether-Sulfide Derivatives, Useful For the Treatment of Inflammatory and Immune Diseases, and Pharmaceutical Compositions Containing Them
09/25/2008US20080234270 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide
09/25/2008US20080234269 N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
09/25/2008US20080234268 Effective for prophylaxis and treatment of diseases, such as ("c-Met") hepatocyte growth factor receptor mediated diseases; N-(4-(3-amino-1H-indazol-4-yl)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide; treatment of neoplasia selected from lung, breast, colon cancer
09/25/2008US20080234267 Substituted 4-(3-hydroxyanilino)quinoline compounds are potent inhibitors of ret (REarranged during Transfection) kinase and thus are potentially useful in treatment of disorders associated with inappropriate ret kinase activity including thyroid cancer, in particular, multiple endocrine neoplasia
09/25/2008US20080234266 Squaric Acid Derivatives II
09/25/2008US20080234265 combination of at least one selective histone deacetylase inhibitor (suberoylanilidine hydroxamic acid, valproic acid) and kinase inhibitor with anti-EGFR activity (gefitinib, erlotinib); anticarcinogenic agent; non-small cell lung, breast, bladder, colon, prostate, uterine, cervical, ovarian cancer
09/25/2008US20080234264 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
09/25/2008US20080234263 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
09/25/2008US20080234262 For treating Mammalian Target of Rapamycin (mTOR)-related disorders and phosphatidylinositol-3 kinase ("PI3K")-related disorders; N-{3-[1-(1-benzylpiperidin-4-yl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl}-N'-methylurea; anticarcinogenic agents, antiinflammatory agents
09/25/2008US20080234261 Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors
09/25/2008US20080234260 Cysteine Protease inhibitors
09/25/2008US20080234259 CB2 agonists; pain, neurodegenative disorders, eating disorders, weight loss or control, obesity, dyslipidemia, drug abuse, vision defect, neurodegenerative diseases; 5-(2,4-difluorophenyl)-4,5-diazatricyclo[5.2.1.0.sup.2,6.]deca-2-(6),3-dien-3-yl-phenylmethanone; antiinflammatory agent, antidepressant
09/25/2008US20080234258 Dihydroxyanthraquinones and Their Use
09/25/2008US20080234257 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
09/25/2008US20080234256 Antibacterial Agents
09/25/2008US20080234255 Polo-like kinase inhibitor, antitumor agent, antiproliferative agent for treating breast, colon, lung and prostate tumors; 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-3-methoxy-benzoic acid; chemical intermediates
09/25/2008US20080234254 anticarcinogenic agents for treating leukaemia, non-small cell lung cancers, colonic cancers, breast cancers, ovarian cancers, renal cancers and melanoma; in vivo hydrolysable ester or amide; N-(2-amino-phenyl)-4-[1-(3,4-dihydroisoquinolin-2(1H)-ylmethyl)vinyl]benzamide; solid phase synthesis
09/25/2008US20080234253 Alzheimer's disease, stroke, traumatic brain injury, and depression, neurodegenerative diseases; antidepressants; a phenyl thiourea or urea derivatives; promote cell proliferation of stem or progenitor cells
09/25/2008US20080234252 2-[4-(4-Chlorophenyl)-5-(methoxymethyl)-4H-1,2,4-triazol-3-yl]isoindoline; vasopressin antagonists; dysmenorrhea, Alzheimer's disease, anorexia nervosa, anxiety, anxiety disorder, asthma, atherosclerosis, autism, cardiovascular disease
09/25/2008US20080234251 8-Substituted Benzoazepines as Toll-Like Receptor Modulators
09/25/2008US20080234250 Heterocyclic Condensed Compounds Useful as Antidiuretic Agents
09/25/2008US20080234249 Cyclic 11-beta hydroxysteroid dehydrogenase type i inhibitors
09/25/2008US20080234248 1,4-Diphenyl-3-substituted azetidin-2-ones; can be metabolized in vivo to form a sterol and/or stanol absorption inhibitor and a sterol biosynthesis inhibitor for treatment of atherosclerosis, hypercholesterolemia, or sitosterolemia
09/25/2008US20080234247 Heterocyclic analgesic compounds and methods of use thereof
09/25/2008US20080234246 Benzoquinone imine-containing ansamycins and its acylation or alkylation derivatives; cellular proliferation, hyperproliferation; increase the bioavailability and reduce the toxicity associated with the natural product
09/25/2008US20080234245 Angiostatic Agents for Controlling Choroidal Neovascularisation After Ocular Surgery or Trauma
09/25/2008US20080234244 Inhibit growth of cancer cells; modulate signal molecules Raf, Mek1, Mek2, Erk1, Erk2 and STAT3; purafied nutraceutical extract;
09/25/2008US20080234243 Method of treating amyloidosis mediated diseases
09/25/2008US20080234242 angiogenesis inhibitor; antiinflammatory agents; immunosuppressants; steroids conjugated compound
09/25/2008US20080234241 Melanogenesis inhibitors and whitening agents comprising ergosterol derivative and compositions containing ergosterol derivative
09/25/2008US20080234240 hormonal treatment over a desired period of time longer than 21-28 days; inhibiting ovulation in human; birth control
09/25/2008US20080234239 Polyaphron dispersion, vitamin D or vitamin D analogue and a corticosteroid; use in the treatment of psoriasis
09/25/2008US20080234238 Multiple daily sequential dosages of genistein and a progestin such as norgestimate, levonorgestrel, norgestrel, norethindrone, desogestrel, gestodene, dienogest, or drospirenone, and optionally a Vitamin D compound; hormone replacement therapy
09/25/2008US20080234237 selectively inhibit neuronal nitric oxide synthase in combination with other pharmaceutically active agents; antidepressants
09/25/2008US20080234236 Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
09/25/2008US20080234234 from endogenous or exogenous stem/progenitor cells and to normalize blood cell and platelet counts; e.g. [3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)-2-hydroxypropyl]trimethylammonium chloride; antitumor and AIDS agent; low toxicity, side effect reduction
09/25/2008US20080234233 N-arylsalicylamide derivatives and hydroxyaryl derivatives; inhibitory activities against AP-1 activation and against NF- kappa B
09/25/2008US20080234232 Methods and compositions for targeting AFAP
09/25/2008US20080234231 Diethyl[2-({[7-[(4-fluorophenyl)methyl]-4-hydroxy-3-({[2-(methyloxy)ethyl]amino}carbonyl)-2-oxo-1,5-naphthyridin-1(2H)-yl]acetyl}amino)ethyl]phosphonate; alone or with a second enzyme inhibitor
09/25/2008US20080234230 Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator
09/25/2008US20080234229 Boronate naphthalene derivaties and other active compounds; pharmaceutical; cosmeceutical; modulators of gene expression; interfering with cellular signal transduction cascades
09/25/2008US20080234228 Boronic acid salts
09/25/2008US20080234227 Biocompatible polymers based on dextran; administration of active ingredient(s) (AI) to humans or to animals for therapeutic and prophylactic purposes
09/25/2008US20080234226 Use Of Iron(III) Complex Compounds For The Preparation Of A Medicament For Oral Treatment Of Iron Deficiency States In Patients With Chronic Inflammatory Bowel Disease
09/25/2008US20080234225 Cromolyn sodium and cyclodextrin stratum corneum penetrating agent to treat, prevent diaper rash, bed soars, decubitus ulcers, skin lesions
09/25/2008US20080234224 Multi-branched polysaccharide derivative; 1,6-anhydrosaccharide; cosmetics give moisture and turgor to the skin
09/25/2008US20080234223 5-azacytidine pyrimidine analog is epigenetic agent histone deacetylase inhibitor; inhibits nucleic acid methylation through an N4 carboxylester or ester bond; acetylcholine cell-targeting agent; cell expresses acetylcholinesterase; central nervous system; liver cancer
09/25/2008US20080234222 Polylysine and polyethylenimine complex of a therapeutic nucleic acid, a polycationic block copolymer, and a polyanionic block copolymer; dosage form for delivering the nucleic acid to a cell in vivo
09/25/2008US20080234221 Transferring agent into cells; using polypeptides, polynucleotides, antibodies nucleic acids ; tumor suppressor gene; anticancer agents
09/25/2008US20080234220 Reducing flavivirus or Hepatitis virus replication in vitro or vivo by inhibiting activity of a microRNA; administering an antisense oligonucleotide complementary to microR-122
09/25/2008US20080234219 TGF- beta binding proteins which can be utilized to increase bone mineralization, and thus may be utilized in treating osteopenia, osteoporosis and bone fractures
09/25/2008US20080234218 Sirna For Inhibiting Il-6 Expression and Composition Containing Them
09/25/2008US20080234217 Double stranded nucleotide sequences for use as tools in tissue targeted gene expression inhibition and treatment of cancer, vascular, neuronal and endocrine diseases
09/25/2008US20080234216 TGF-beta type receptor cDNAs encoded products and uses therefor
09/25/2008US20080234215 DNA composition and uses thereof
09/25/2008US20080234214 Seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages; antisense agents for gene expression inhibition of a wide variety of pathological disorders such as autoimmune diseases; suitable for oral administration
09/25/2008US20080234213 Oncogenic regulatory RNAs for diagnostics and therapeutics